EU Pharmacovigilance Inspection Findings
Explore all topics, guides, and frameworks related to EU Pharmacovigilance Inspection Findings.
Articles in this section
6- EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls Learn how lifecycle transitions such as transfers, acquisitions, divestments, new indications and system changes can affect pharmacovigilance responsibilities, records and oversight. Read Article →
- EU Pharmacovigilance Inspection Findings: Training, Competence and Qualified Personnel Learn why training completion is not the same as competence and how inspectors can evaluate role-based training, performance, effectiveness and QPPV oversight. Read Article →
- EU Pharmacovigilance Inspection Findings: Data Integrity, Traceability and the Evidence Chain Learn how source data, system interfaces, audit trails, reconciliations, changes and retained records contribute to a reliable pharmacovigilance evidence chain. Read Article →
- EU Pharmacovigilance Inspection Findings: CAPA Effectiveness and Recurrence of Deficiencies Learn how to distinguish CAPA completion from effectiveness and how recurrence, scope, root cause and verification are assessed during pharmacovigilance inspection follow-up. Read Article →
- EU Pharmacovigilance Compliance Monitoring: Detecting Failures Before Inspection Learn how monitoring differs from audit and inspection and how meaningful indicators, thresholds, trends and escalation support effective pharmacovigilance oversight. Read Article →
- EU Pharmacovigilance Inspection Findings: Benefit–Risk Assessment and Decision-Making Learn how inspectors can evaluate the process and evidence behind pharmacovigilance decisions while distinguishing scientific uncertainty from deficiencies in process control. Read Article →